Functional analysis of interaction between DOPA and Glutamate neurotransmission in the nucleus tractus solitarii
| Project/Area Number |
15K21273
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
General pharmacology
Neurochemistry/Neuropharmacology
|
|---|
| Research Institution | Yokohama City University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2017: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2016: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | L-DOPA / Glutamate / GPR143 / 下位脳幹弧束核 / 圧受容器反射 / 自律神経 / NTS / blood pressure / primary affarent / OA1 / NMDA / 延髄弧束核 / 心血管応答中枢 |
|---|
| Outline of Final Research Achievements |
Levodopa (DOPA) is currently the most used treatment for Parkinson's disease. We have hypothesis that DOPA is a neurotransmitter in the brain. In this study, we demonstrated that DOPA potentiates the action of glutamate in the nucleus tractus solitarii, which controls central blood pressure regulation.
We also identified the role of DOPA in cardiovascular regulation. We demonstrated that DOPA augments the action of the adrenergic α1 receptor through a DOPA receptor GPR143. It suggested that this mechanism may be involved in diurnal variation of blood pressure.
These findings indicate that DOPA plays an important role in physiological blood pressure control.
|
Report
(4 results)
Research Products
(5 results)
